Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) fell 4.5% during trading on Tuesday . The stock traded as low as $12.68 and last traded at $12.88. 52,442 shares changed hands during trading, a decline of 85% from the average session volume of 342,036 shares. The stock had previously closed at $13.48.
Analyst Ratings Changes
Several brokerages have recently commented on BCAX. HC Wainwright boosted their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, January 27th. Wedbush reaffirmed an "outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. RODMAN&RENSHAW raised Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. Finally, Rodman & Renshaw assumed coverage on Bicara Therapeutics in a research note on Tuesday, November 5th. They issued a "buy" rating and a $48.00 target price for the company. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $41.20.
Read Our Latest Research Report on Bicara Therapeutics
Bicara Therapeutics Stock Down 5.9 %
The stock's 50-day moving average is $14.40.
Institutional Trading of Bicara Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Turn Management LLC bought a new stake in Bicara Therapeutics in the third quarter valued at approximately $14,324,000. Geode Capital Management LLC bought a new stake in Bicara Therapeutics in the third quarter valued at approximately $1,239,000. Vestal Point Capital LP bought a new stake in Bicara Therapeutics in the third quarter valued at approximately $10,825,000. FMR LLC bought a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $57,913,000. Finally, Braidwell LP bought a new position in shares of Bicara Therapeutics during the third quarter valued at approximately $42,219,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Stories
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.